EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Blood DDIT4 and TRIM13 Transcript Levels Mark the Early Stages of Machado–Joseph Disease

Ana F Ferreira, Mafalda Raposo, Emily D Shaw, Louisa Liu, João Vasconcelos, Teresa Kay, Conceição Bettencourt, Maria Luiza Saraiva-Pereira, Laura Bannach Jardim iD, Maria do Carmo Costa iD, Manuela Lima

Annals of Neurology · 2025

DOI: 10.1002/ana.27222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2025. Verfasst von Ana F Ferreira und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal. Hauptthemen laut MEDLINE: Transcription Factors, Machado-Joseph Disease, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alzheimer's Research UK, ESMI, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu); ESMI project was supported through the following funding org…, Heeringa Ataxia Research Fund, University of Michigan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

An abundance of select transcripts and proteins has been found to be dysregulated in blood samples of Machado–Joseph disease (MJD) carriers. Here, we aimed to: (1) identify blood transcriptional changes as potential biomarkers of MJD; (2) correlate levels of differentially expressed blood transcripts with MJD carriers features; and (3) evaluate whether the identified differential abundance of blood transcripts in MJD patients is preserved in MJD brains.

Methods

We used unbiased RNA microarray and quantitative polymerase chain reaction to assess transcript levels in blood and brain samples, and western blot analysis to evaluate the abundance of specific proteins in brain samples.

Results

We observed consistent dysregulation of DDIT4 , TRIM13 , and P2RY13 transcriptional levels in the blood of MJD patients from preclinical to symptomatic stages in Azorean and Brazilian cohorts. Combined blood DDIT4 and TRIM13 transcriptional levels show a very high accuracy to discriminate MJD carriers from matched controls (AUC ≥0.90). Levels of P2RY13 transcripts correlate with age at onset, and an abundance of DDIT4 and TRIM13 transcripts correlate with the expanded CAG repeat size in combined Azorean and Brazilian patients; and levels of TRIM13 transcripts correlate with age at onset of early‐stage Azorean patients. Moreover, the abundance of TRIM13 protein is increased in the cerebral cortex of MJD patients.

Interpretation

Overall, blood DDIT4 and TRIM13 transcript levels are potential biomarkers of MJD. Cellular processes involving DDIT4 , TRIM13 , and P2RY13 appear to be commonly dysregulated in the blood and brain of MJD patients, indicating the involvement of these genes in MJD pathogenesis. ANN NEUROL 2025;98:107–119

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsMachado-Joseph DiseaseUbiquitin-Protein LigasesHumansMaleFemaleAdultMiddle AgedBiomarkersTripartite Motif ProteinsYoung AdultBrainRNA, Messenger

Substanzen

Transcription FactorsUbiquitin-Protein LigasesBiomarkersTripartite Motif ProteinsRNA, Messenger

Autor:innen und Institutionen

  • Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
  • UMIB-Unit for Multidisciplinary Research in Biomedicine, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal.
  • Instituto de Biologia Molecular e Celular (IBMC), Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.
  • Department of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Serviço de Neurologia, Hospital do Divino Espírito Santo (HDES), Ponta Delgada, Portugal.
  • Serviço de Genética Clínica, Hospital Dona Estefânia, Lisbon, Portugal.

ORCID-Profile: Laura Bannach Jardim, Maria do Carmo Costa

Förderung

  • Alzheimer's Research UK
  • ESMI, an EU Joint Programme - Neurodegenerative Disease Research (JPND) project (see www.jpnd.eu); ESMI project was supported through the following funding org…
  • Heeringa Ataxia Research Fund, University of Michigan
  • Fundação para a Ciência e Tecnologia
  • Multiple System Atrophy Trust (UK)
  • NIA NIH HHS

Zitieren

APA

Ferreira, A. F., Raposo, M., Shaw, E. D., Liu, L., Vasconcelos, J., Kay, T., Bettencourt, C., Saraiva-Pereira, M. L., Jardim, L. B., Costa, M. D. C., & Lima, M. (2025). Blood DDIT4 and TRIM13 Transcript Levels Mark the Early Stages of Machado–Joseph Disease. Annals of Neurology. https://doi.org/10.1002/ana.27222

Vancouver

Ferreira AF, Raposo M, Shaw ED, Liu L, Vasconcelos J, Kay T, et al. Blood DDIT4 and TRIM13 Transcript Levels Mark the Early Stages of Machado–Joseph Disease. Annals of Neurology. 2025. doi:10.1002/ana.27222

BibTeX
@article{Ferreira2025,
  author = {Ferreira, Ana F and Raposo, Mafalda and Shaw, Emily D and Liu, Louisa and Vasconcelos, João and Kay, Teresa and Bettencourt, Conceição and Saraiva-Pereira, Maria Luiza and Jardim, Laura Bannach and Costa, Maria do Carmo and Lima, Manuela},
  title = {Blood DDIT4 and TRIM13 Transcript Levels Mark the Early Stages of Machado–Joseph Disease},
  journal = {Annals of Neurology},
  year = {2025},
  doi = {10.1002/ana.27222}
}
Kostenlos starten →